Search

Author/Creator Vallier, Anne-Laure

1. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

Authors:
Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma...
Journal:
Lancet
Issue:
Volume 393:Issue 10191(2019)
Page Start:
2599
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

Authors:
Earl, Helena M; Hiller, Louise; Vallier, Anne-Laure; Loi, Shrushma; McAdam, Karen; Hughes-Davies, Luke; Harnett, Adrian N; Ah-See, Mei-Lin; Simcock, Richard; Rea, Daniel; Raj, Sanjay; Woodings, Pamela; Harries, Mark; Howe, Donna; Raynes, Kerry; Higgins, Helen B; Wilcox, Maggie; Plummer, Chris; Ma...
Journal:
Lancet
Issue:
Volume 393:Issue 10191(2019)
Page Start:
2599
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A nested cohort study of 6, 248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. Issue 1 (December 2015)

Authors:
Abraham, Jean; Hiller, Louise; Dorling, Leila; Vallier, Anne-Laure; Dunn, Janet; Bowden, Sarah; Ingle, Susan; Jones, Linda; Hardy, Richard; Twelves, Christopher; Poole, Christopher; Pharoah, Paul; Caldas, Carlos; Earl, Helena
Journal:
BMC medicine
Issue:
Volume 13:Issue 1(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Issue 1 (December 2016)

Authors:
Ali, H.; Dariush, Aliakbar; Provenzano, Elena; Bardwell, Helen; Abraham, Jean; Iddawela, Mahesh; Vallier, Anne-Laure; Hiller, Louise; Dunn, Janet.; Bowden, Sarah; Hickish, Tamas; McAdam, Karen; Houston, Stephen; Irwin, Mike; Pharoah, Paul; Brenton, James; Walton, Nicholas; Earl, Helena; Caldas, C...
Journal:
Breast cancer research
Issue:
Volume 18:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Issue 6 (June 2015)

Authors:
Earl, Helena M; Hiller, Louise; Dunn, Janet A; Blenkinsop, Clare; Grybowicz, Louise; Vallier, Anne-Laure; Abraham, Jean; Thomas, Jeremy; Provenzano, Elena; Hughes-Davies, Luke; Gounaris, Ioannis; McAdam, Karen; Chan, Stephen; Ahmad, Rizvana; Hickish, Tamas; Houston, Stephen; Rea, Daniel; Bartlett...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 6(2015:Jun.)
Page Start:
656
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗